Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YN5T
|
|||
| Drug Name |
Selumetinib
|
|||
| Synonyms |
Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neurofibromatosis type 1 [ICD-11: LD2D.10; ICD-10: Q85.0] | Approved | [1] | |
| Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] | Investigative | [2] | ||
| Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] | Investigative | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H15BrClFN4O3
|
|||
| Canonical SMILES |
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
|
|||
| InChI |
1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
|
|||
| InChIKey |
CYOHGALHFOKKQC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 606143-52-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15117183, 22530930, 39966063, 53837732, 57374224, 76853338, 91146061, 99431772, 123051124, 124490406, 124756930, 124899407, 124963590, 125163737, 125329930, 125569760, 126580498, 126644899, 126665950, 126737693, 131465101, 131477688, 135262198, 135344948, 135602608, 135685252, 135685253, 135685272, 135686160, 135686161, 135686182, 135686183, 135727389, 136368075, 136920282, 136959521, 137220034, 139721905, 143499011, 144115657, 144206913, 152043674, 152235945, 152258818, 152344235, 160647668, 160813024, 162011399, 162037381, 162200063
|
|||
| ChEBI ID |
CHEBI:90227
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN ERK activator kinase 1 (MEK1) | Target Info | Inhibitor | [2] |
| HUMAN ERK activator kinase 2 (MEK2) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.